You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder
|
|---|---|
| Published in |
CNS Drugs, December 2012
|
| DOI | 10.2165/11633900-000000000-00000 |
| Pubmed ID | |
| Authors |
Eric Q. Wu, Paul Hodgkins, Rym Ben-Hamadi, Juliana Setyawan, Jipan Xie, Vanja Sikirica, Ella X. Du, Sherry Y. Yan, M. Haim Erder |
| Abstract |
Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder that impairs the quality of life for patients and their families and is associated with considerable direct and indirect costs. Pharmacotherapies for ADHD, including stimulants and non-stimulants, are often used to treat patients with ADHD. However, the costs, effectiveness and adverse effects of these agents vary. Therefore, information regarding the cost effectiveness of different pharmacological treatments is needed to better inform payers in the allocation of limited resources. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 3% |
| Brazil | 2 | 1% |
| Unknown | 138 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 21% |
| Student > Master | 21 | 15% |
| Student > Ph. D. Student | 17 | 12% |
| Other | 14 | 10% |
| Student > Bachelor | 12 | 8% |
| Other | 25 | 17% |
| Unknown | 25 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 26% |
| Psychology | 29 | 20% |
| Nursing and Health Professions | 8 | 6% |
| Economics, Econometrics and Finance | 8 | 6% |
| Social Sciences | 6 | 4% |
| Other | 25 | 17% |
| Unknown | 31 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2020.
All research outputs
#2,517,408
of 26,017,215 outputs
Outputs from CNS Drugs
#201
of 1,413 outputs
Outputs of similar age
#23,713
of 295,098 outputs
Outputs of similar age from CNS Drugs
#7
of 68 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,413 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,098 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.